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Abstract
Background: Mutations at splice junctions causing exon skipping are uncommon compared to
exonic mutations, and two intronic mutations causing an aberrant phenotype have rarely been
reported. Despite the high number of functional ABCA1 mutations reported to date, splice variants
have been reported infrequently. We screened DNA from a 41 year-old male with low HDL-C (12
mg/dL [0.31 mmol/L]) and a family history of premature coronary heart disease (CHD) using
polymerase chain reaction single-strand conformation polymorphism (SSCP) analysis.
Methods: Family members with low levels of HDL-C (n = 6) were screened by SSCP for mutations
in ABCA1. Samples with altered SSCP patterns were sequenced directly using either an ABI 3700
or ABI3730Xl DNA Analyzer. To screen for splicing defects, cDNA was isolated from the
proband's RNA and was sequenced as above. A series of minigenes were constructed to determine
the contribution of normal and defective alleles.
Results: Two novel splice variants in ABCA1 were identified. The first mutation was a single base
pair change (T->C) in IVS 7, 6 bps downstream from the exon7/intron7 junction. Amplification of
cDNA and allelic subcloning identified skipping of Exon 7 that results in the elimination of 59 amino
acids from the first extracellular loop of the ABCA1 protein. The second mutation was a single base
pair change (G->C) at IVS 31 -1, at the intron/exon junction of exon 32. This mutation causes
skipping of exon 32, resulting in 8 novel amino acids followed by a stop codon and a predicted
protein size of 1496 AA, compared to normal (2261 AA). Bioinformatic studies predicted an impact
on splicing as confirmed by in vitro assays of constitutive splicing.
Conclusion: In addition to carnitine-acylcarnitine translocase (CACT) deficiency and HermanskyPudlak syndrome type 3, this represents only the third reported case in which 2 different splice
mutations has resulted in an aberrant clinical phenotype.
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Background
Epidemiologic studies have demonstrated an inverse association between high-density lipoprotein cholesterol
(HDL-C) and coronary heart disease (CHD) [1].
Although low HDL-C is represented by polygenic influences in the majority of cases [2], up to 10% of the general
population may have a monogenic abnormality that produces the low HDL-C phenotype [3]. Of the primary candidate genes regulating HDL metabolism, mutations in
ABCA1 are the most frequent, accounting for the vast
majority of HDL-C deficiency states [3-5]. In the absence
of genotypic variation or post-translational modification
[6], the encoded 220-kDa glycoprotein mediates efflux of
cholesterol and phospholipid from macrophages serving
as the initial step of reverse cholesterol transport [7].
However, in the presence of defective ABCA1, lipid accumulation may occur in both reticuloendothelial organs
and the vasculature [8]. Herein, we report a family with
low HDL-C, premature CHD and 2 novel mutations that
are both outside ABCA1 coding regions.

Methods
Study subjects
The proband, a 41-year old resident of Virginia, USA, was
referred for further evaluation after noted to have reduced
HDL cholesterol that varied between 12–18 mg/dL [0.31–
0.47 mmol/L]. The patient reported no history of cigarette
smoking, hypertension, or diabetes mellitus. Moreover,
he has no personal history of symptomatic CHD and is
physically active bicycling up to 5 times weekly. There is a
family history of premature CHD, characterized by a
maternal grandfather who reportedly suffered a myocardial infarction at age 35 years and a maternal brother who
underwent percutaneous coronary intervention and stent
placement for coronary artery disease at age 56 years. The
proband's parents are both living and without symptomatic CHD as are his 2 siblings. A pedigree of the proband
and family members participating in the study is shown in
Figure 1. On physical examination, the proband did not
evidence mucosal discoloration, hepatosplenomegaly or
peripheral neuropathy. The protocol was approved by the
University of Maryland Institutional Review Board and all
subjects gave their informed consent before participation.
Determination of levels of plasma lipids and lipoproteins
Blood samples were collected after a 12-hour overnight
fast. Levels of plasma total cholesterol and triglyceride
were measured using enzymatic/colorimetric methods
with the Vitros 950 Chemistry Analyzer (Johnson & Johnson, New Brunswick, NJ). HDL-C was determined by the
heparin-manganese precipitation method and apolipoproteins A-I and B were measured using a radial immunodiffusion assay [9]. LDL-C was estimated using the
Friedewald formula [10].

http://www.biomedcentral.com/1471-2350/10/1

Mutation analysis
PCR amplification and Single-Strand Conformation Polymorphism
(SSCP) analysis
All exons of ABCA1 were amplified by PCR from genomic
DNA using primers and reaction conditions as previously
described [11]. PCR primers amplified all coding regions,
splice site junctions, and intronic regions spanning at least
50 nucleotides upstream to the intron-exon junction.
Exons of ABCA1 were designated using established
nomenclature [12]. For mutation analysis of ABCA1, PCR
products were mixed with 6x loading dye (95% formamide, 20 mmol/L EDTA, 0.05% bromophenol blue,
0.05% xylene cyanol FF), denatured for 10 minutes at
96°C, and placed on ice. SSCP samples were prepared and
electrophoresed using nondenaturing 8% or 10% polyacrylamide gels at 5 to 10 watts for approximately 24 hours
at room temperature and processed [5].
Sequencing of PCR amplified DNA
PCR products showing SSCP shifts of ABCA1 were isolated using the Qiagen PCR purification kit and
sequenced on an ABI 3700 or ABI3730Xl DNA Analyzer.
To rule out changes in other primary HDL candidate
genes, all exons and exon-intron boundary regions
(including at least 50 bp into the intron region) of the
apolipoprotein A-I and lecithin cholesterol acyl transferase (LCAT) genes were amplified and sequenced from
proband DNA.
Total RNA isolation, cDNA synthesis, and segment amplification
Blood samples were collected into PAXgene Blood RNA
tubes (Qiagen, Valencia, CA., USA) from the proband and
biologic family members. Total RNA was isolated from
the PAXgene tubes using the PAXgene Blood RNA Kit
(PreAnalytix/Qiagen, Valencia, Ca., USA). Subsequently,
first-strand cDNA synthesis was carried out with the
Advantage RT-for-PCR Kit (BD Biosciences, Palo Alto,
CA), using oligo dT primers included in the kit.

There were two specific areas of interest in the ABCA1
gene that were examined. The region surrounding exon 7
(exon 6 through exon 8) was amplified from cDNA using
the following primers: 5'- TGAAGCTTCAAGATTTCCTGG3' (forward primer in exon 6), and 5'-CTCCTGGGCCAGAGTCCCAAG-3' (reverse primer in exon 8). The region
surrounding exon 32 (exon 30 through exon 33) was
amplified from cDNA using the following primers: 5'GCTCCTGAGGACACGGGAACC-3' (forward primer in
exon 30), and 5'-CTCATTCACCCAGATCTTGTTC-3'
(reverse primer in exon 33) PCR was performed using 20
pmol of each primer in a total volume of 50 μL containing
0.4 mM each dNTP, 100 ng cDNA, 1.0 U of AmpliTaq
Gold (Applied Biosystems, Foster City, CA 94404 USA),
in 1× Gold Buffer, containing 15 mM Tris-Cl pH8.0, 50
mM KCl and 2.0 mM MgCl2+ (Applied Biosystems). The
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Figure 1structure of kindred with 2 novel ABCA1 splice-site mutations
Pedigree
Pedigree structure of kindred with 2 novel ABCA1 splice-site mutations.

PCR reaction was carried out in a Techne Genius Thermocycler (Techne Inc, Princeton, NJ), consisting of an initial
denaturation step of 95°C for 10 minutes, followed by 35
cycles: denaturation at 94°C for 30 seconds, annealing at
57.5°C for 30 seconds, and extension at 72°C for 45 seconds. A final extension step at 72°C for 5 minutes followed the last PCR cycle. PCR products were separated on
a 16% acrylamide gel. The ratios of PCR amplification
products were determined by densitometry using the VersaDoc Imaging System (Bio-Rad Laboratories, Hercules,
CA.).

Qiaquick PCR Purification Kit (Qiagen, Inc, Valencia,
CA.). The PCR products were then cloned into a pDrive
Cloning Vector, Qiagen PCR Cloningplus Kit (Qiagen,
Inc, Valencia, CA.), plated, and grown overnight. Positive
colonies were PCR-screened using the primers listed
above. Colonies were grown overnight in 5 mL of LB
media at 37°C, with shaking at 220 rpm. Plasmid DNA
was isolated using the Quantum Prep Plasmid Miniprep
Kit (Bio-Rad Laboratories, Hercules, CA). Sequencing was
performed using an ABI 3700 or ABI3730Xl DNA Analyzer.

Cleaning, cloning and screening of ABCA1 cDNA fragments
Following PCR, ABCA1 cDNA fragments containing exons
6–8, and 30–33 were cleaned for cloning with the

Splice site analysis
Both of the base pair changes were analyzed using either
the Automated Splice Site Analysis server at https://
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splice.uwo.ca at The University of Western Ontario [13] or
the Delila servers [14,15] that also uses information theory methods to identify binding sites on DNA or RNA.

Buffer, 2.0 mM MgCl2, and 1.25 U AmpliTaq Gold.
Amplified cDNA included the proband and lab controls
with normal HDL-C.

Constitutive splicing evaluation
Primer design and sequences
In addition to the proband and family members, 20 unrelated control samples with various HDL-C levels were
used for the constitutive splicing analysis. All of the
intron/exon junctions in ABCA1 were analyzed using the
servers listed above to determine the information content
of splice-site junctions. Low acceptor Ri values indicated
potential regions of abnormal splicing (Table 1). Primers
were then designed to evaluate these regions and determine the extent of constitutive splicing (Table 2).

Band excision, purification and re-amplification
Bands corresponding to un-expected amplicon sizes were
excised and purified using the QIAEX II Gel Extraction Kit
(Qiagen Inc., 27220 Turnberry Lane Suite 200 Valencia,
CA 91355). Because of insufficient purified DNA from the
bands to permit successful cloning, the DNA was reamplified using the same original amplification conditions and used directly for cloning.

Amplification details
Regions of cDNA were amplified using the primers listed
above. PCR cycling conditions included initial denaturation at 95°C for 10 min, followed by 35 cycles of 95°C for
30 s, 55°C for 30 s, and 72°C between 30 s to 1.0 min
(depending upon the length of the amplicon) with an
additional extension of 72°C for 5 min. Amplifications
were performed in a Techne Genius thermocycler
(Techne, Burlington, NJ, USA). Samples were amplified
using 50 μl reaction volumes consisting of 20 to 100 ng
cDNA, 10 pmol each primer, 0.2 mM each dNTP, 1× Gold

Cloning and colony screening
PCR fragments were cloned into the pJET1 vector (Fermentas Inc., 7520 Connelley Drive, Hanover, MD
21076). Colony screening was performed using the same
amplification conditions to test for successful DNA fragment insertion into the pJET1 Cloning Vector.
Plasmid mini-prep preparation and sequencing
Positive colonies were grown O/N at 37C. Plasmid minipreps were prepared using the Quantum Prep Plasmid
Miniprep Kit (Bio-Rad Laboratories, 2000 Alfred Nobel
Drive, Hercules CA, 94547). Plasmids were subjected to
direct sequencing in both directions using the primers
listed above, as well as, in some cases, primers specific for

Table 1: Tabular representation of the information content for all acceptor intron/exon junctions of ABCA1.

Intron
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Acceptor Ri value (bits)
12.7
8.2
8.1
10.7
2.2
5.8
12.0
5.9
12.4
8.7
3.2
6.0
5.8
8.5
11.9
9.6
9.7
11.7
10.9
9.2
13.0
8.2
12.2
11.2
13.7

Intron
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Acceptor Ri value (bits)
10.5
8.5
1.2
6.1
14.4
3.4
13.6
6.5
7.9
11.7
14.0
9.1
11.7
17.1
5.3
11.9
9.6
11.4
11.5
8.6
9.5
10.2
12.7
7.3

The four junctions (in bold) were further examined for aberrant splicing events.
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Table 2: Primers to ABCA1 in regions predicting constitutive splicing defects

Name

Sequence

ABC-A1Ex4FcDNA
ABC-A1Ex8RcDNA

5'-GCCATTTTCCAAATAAAGCCATGCC-3'
5'-CTCCTGGGCGAGAGTCCCAAG-3'

ABC-A1Ex10FcDNA
ABC-A1Ex14RcDNA

5'-CTCCTTACTGCAATGATTTGATGAA-3'
5'-CCGCATGTCCTCAAAGGGGTCAGC-3'

ABC-A1Ex27FcDNA
ABC-A1Ex30RcDNA

5'-ATGGTACCTTGCCAGCAAGACGAA-3'
5'-GGGATTGGGTTTCCTTCCATACAG-3'

ABC-A1Ex30FcDNA
ABC-A1Ex33RcDNA

5'-GCTCCTGAGGACACGGGAACC-3'
5'-CTCATTCACCCAGATCTTGTTC-3'

the pJET vector (pJET1-Forward and pJET1-Reverse).
Sequencing reactions were cleaned using Performa V3 96Well Short Plates (Edge BioSystems, 201 Perry Parkway,
Suite 5 Gaithersburg, MD 20877) and run on an ABI
3730XL automated sequencer (Applied Biosystems, Foster
City, CA, USA).
Construction of ABCA1 minigenes
To investigate the precise contribution to aberrant splicing
of each of the two intronic mutations (IVS7 +6t>c and
IVS31-1g>c), wild-type and mutant ABCA1 minigenes
were constructed using the proband's gDNA as a template.
The first pair of constructs were designated WT_IVS311g>c (wild-type) and MT_IVS31-1g>c (mutant). These
two constructs were amplified using forward primer
(IVS30) 5'-GGGCATACACCTCCATGAAGGCAG-3' and
the reverse primer (IVS34A) 5'-ATGAGCTGCCAGGTGATCCGTTTA-3'. PCR cycling conditions included initial
denaturation at 92°C for 5 min, followed by 35 cycles of
95°C for 30 s, 55°C for 30 s, and 72°C for 5.0 min, with
an additional extension of 72°C for 10 min. Samples were
amplified using 50 μl reaction volumes consisting of 100
ng gDNA, 10 pmol each primer, 0.2 mM each dNTP, 1×
Dynazyme EXT buffer (F-514), and 1.0 U Dynazyme

EXT(New England Biolabs, Ipswich, MA, USA). This insert
was composed of a small portion of the 5' end of intron
30, exon 31, intron 31, exon 32, intron 32, exon 33,
intron 33, exon 34, and the 3' portion of intron 34, and is
4.87 kb in size. The two constructs were then cloned into
the pTargeT vector (Promega) for minigene expression
studies.
The second pair of constructs were designated WT_ IVS7
+6t>c (wild-type) and MT_ IVS7 +6t>c (mutant). Because
several intronic regions were too large to be incorporated
in the vector (IVS6, 2.98kb; IVS7, 12.96 kb; and IVS8, 4.96
kb) truncated intronic regions of approximately 400 bp
were used (see Primers, Table 3).
PCR cycling conditions included initial denaturation at
95°C for 10 min, followed by 35 cycles of 95°C for 30 s,
55°C for 30 s, and 72°C for 45s, with an additional extension of 72°C for 5 min. Amplifications were performed in
a Techne Genius thermocycler (Techne, Burlington, NJ,
USA). Samples were amplified using 50 μl reaction volumes consisting of 20 to 100 ng cDNA, 10 pmol each
primer, 0.2 mM each dNTP, 1× Gold Buffer, 2.0 mM
MgCl2, and 1.25 U AmpliTaq Gold. Four segments were

Table 3: Primers used for construct amplification of the IVS7 variant

Segment 1
IVS 5-3' BamHI
IVS6-5' XhoI

Primer Sequence
5'-GATGGGGATCCCAGCACCATCACACTGTTTGAG-3'
5'-CGGCGCTCGAGGAAATCATCACAAATGCCAAG-3'

Segment 2
IVS 6-3'
IVS 7-5' HindIII

5'-CGCTCGAGGATGTTGTTCATGTAATAAA-3'
5'-CGAAGCTTCCAACTGTGACAGCCCACAA-3'

Segment 3
IVS 7-3' HindIII
IVS 8-5' PvuI

5'-GCAAGCTTGTGAGGCGTCATTAACTTGT-3'
5'-GCCGATCGTTATTCCTGTTAGTTAGCAA-3'

Segment 4
IVS 8-3' PvuI
IVS 9-5'

5'-GCCGATCGGCAGAGGGGTCTCAGAATCC-3'
5'-CCTTCTGCCATTATCTCATTCTTG-3'
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generated; however, only the 3 terminal segments ligated
correctly, and these were cloned into the pTargeT vector.
Segment 1 was redesigned and cloned upstream to the 3
terminal segments. All construct sequences were confirmed by sequencing. The total size of the insert was 3.5
kb in size, which combined with the pTargeT vector (5.69
kb), resulted in a total insert + vector size of 9.19 kb.
Expression of ABCA1 minigenes in transfected cells
COS cells were grown in DMEM containing 5% FBS at
37°C and 5% CO2 and used for transfection. On the day
prior to transfection, 4 × 105 cells were seeded on 6 well
plates in 3.0 milliliters of media. On the day of transfection, 1.5 μg of the pTargeT plasmids containing the various constructs were transfected using Polyfect
Transfection Reagent (Qiagen, Valencia, CA). Forty-eight
hours post transfection, total cellular RNA was isolated
using the High Pure RNA Isolation Kit (Roche, Mannheim
Germany). First-strand cDNA synthesis was carried out
with the Advantage RT-for-PCR Kit (BD Biosciences, Palo
Alto, Ca), using random decamers included in the kit.
cDNA amplification was performed using the appropriate
primer pairs (IVS 7, IVS7 For 5'-TGAAGCTTCAAGATTTCCTGG-3' + IVS7 Rev 5'-CTCCTGGGCCAGAGTCCCAAG3', and for IVS31, IVS31 For 5'-CTGCCAGGCAGGGGAGGAAGAGTG-3' + IVS31 Rev 5'-CTCATTCACCCAGATCTTGTTC-3'). In both cases, a very small amount of
endogenous ABCA1 was amplified from COS1 cells and
was subsequently subtracted from all samples in densitometry analysis.

Results
Levels of lipids, lipoproteins and apolipoproteins AI and
B are shown in Table 4. All family members had reduced

HDL-C and apoAI with the lowest levels identified in the
proband (12 mg/dL [0.31 mmol/L]) and his sister (22
mg/dL [0.57 mmol/L]). An altered SSCP pattern was identified in two regions of ABCA1 encompassing IVS7 and
IVS31 in the proband and affected family members with
low HDL-C but was not observed in an additional 100
screened unrelated subjects. Direct sequencing of these
regions revealed alteration in the splice-site junction suggestive of two novel splice variants in ABCA1.
Splice site analysis
Two servers (Automated Splice Site Analysis server at
https://splice.uwo.ca University of Western Ontario and
the Delila servers) were used to examine both mutation
sites. Analysis of the IVS7 +6t>c mutation predicts a
decrease in the strength of the splice site, from 10.2 bits to
8.8 bits of information, resulting in a 2.7 fold decrease in
binding efficiency and a reduction in binding from 100%
for normal vs. 37.4% for the mutant. This creates a "leaky
site" that would be predicted to adversely affect normal
protein production. Information analysis also predicts the
complete loss of splice site recognition for IVS31-1g>c,
with original information content of the splice site being
reduced from 3.4 bits to -3.9 bits. Both of these predicted
results compare favorably with original densitometry
measures, assuming a somewhat lower stability for malformed proteins [16,17].
Ex Vivo cDNA analysis
The first mutation was a single base pair change (T→C) in
IVS 7, 6 base-pairs downstream from the exon7/intron7
junction (Nomenclature IVS7+6t>c). Following cDNA
amplification, a smaller band corresponding to Exon 7
skipping was observed (Figure 2). Subcloning of alleles

Table 4: Selected baseline characteristics including age (years), body mass index (kg/m2), lipids, lipoproteins (mg/dL and mmol/L)
apolipoproteins (mg/dL) and presence or absence of ABCA1 splice variants of the low HDL pedigree

Relative

Age

BMI

TC

TG

HDL

LDL

ApoAI

ApoB

IVS7+6c>t

IVS31-1g>c

Father (D1)
(mmol/L)

65

38.3

189
4.90

245
2.77

35
0.91

105
2.72

149

110

Yes

No

Mother (D2)
(mmol/L)

63

30.9

155
4.01

293
3.31

31
0.80

65
1.68

139

87

No

Yes

Proband (D3)
(mmol/L)

41

28.2

101
2.62

56
0.63

12
0.31

65
1.68

70

59

Yes

Yes

Sister (D4)
(mmol/L)

37

29.3

149
3.86

70
0.79

22
0.57

113
2.93

73

90

Yes

Yes

Brother (D5)
(mmol/L)

43

34.6

159
4.12

176
1.99

24
0.62

100
2.59

109

94

No

Yes

Daughter (D6)
(mmol/L)

16

74
1.92

42
0.47

35
0.91

31
0.80

100

25

No

Yes
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Exon 7 Skipping
Normal splicing
Exon 6

Exon 7
Exon 6

Exon 7

Exon 8
Exon 8

1

2

3

500bp
389bp

Splicing defect

300bp
250bp
212bp

Exon 6

Exon 7

400bp

Exon 8

Exon 6 Exon 8

200bp
150bp

100bp

…..ATGCATTCTCCACAAGAGAACACTAAACTC…..
Figure 2splicing of exon 7 is illustrated in the top portion of the figure
Normal
Normal splicing of exon 7 is illustrated in the top portion of the figure. Schematic representation of exon 7 skipping
is shown at the lower portion. A 16% acrylamide gel run of the PCR products from cDNA shows the normal splice product of
389 base-pairs and a splice variant band of 212 base-pairs that results in the elimination of 59 amino acids. Lane 1 (control),
Lane 2 (proband). The referent 50 base-pair ladder is shown in lane 3. Sequence of aberrant splicing shown at bottom of figure.

confirmed Exon 7 skipping in one allele that resulted in
the elimination of 59 Amino Acids in the first extracellular
loop of the ABCA1 protein but did not result in a
frameshift or premature truncation. The second mutation
was a single base pair change (G→C) at IVS 31 -1, at the
intron/exon junction of Exon 32 (Nomenclature IVS311g>c) (Figure 3). This mutation causes skipping of exon
32, resulting in 8 novel amino acids followed by a stop
codon with a predicted protein size of 1496AA, compared
to normal (2261AA). In contrast, sequencing of the
APOA1 and LCAT promoter splice and coding regions disclosed no mutations.
Minigene transfection results
Using the minigene construct, the IVS31 splicing defect
demonstrated results as predicted from bioinformatic

analysis. Specifically, the mutant construct revealed 98%
of aberrantly spliced product A by densitometry, with the
remaining 2% comprising the aberrantly spliced product
B (constitutively produced). The wild-type sample
showed 89% of normally spliced product, 9% of aberrantly spliced product A, with the remaining 2% of the
other species (B) of aberrantly spliced product (Figure 4)
for sequence of included intron 31 base pairs. This demonstrates that the mutation in question (IVS31-1g>c)
completely abolishes normal splicing, and confirms the
results generated using Automated Splice Site Analysis.
This result is consistent with the original observation of
constitutive aberrant splicing at a low level. In contrast,
the IVS7 mutation did not reveal the level of mis-splicing
anticipated from cDNA analysis because only 2–3% of
defective product was detected.
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Exon 32 Skipping
Normal splicing
1

Exon 31

Exon 32

2

405bp

Exon 31

Exon 32

3

Exon 33
400bp

Exon 33
310bp
300bp

Splicing defect

Exon 31

Exon 32

8 novel amino acids,
followed by stop codon

250bp

8 AA frag STOP

Exon 31

8 AA frag

STOP

….CTGCCTCCTCCACAACTTAAAGAACAAGATCTGGGTGAATGA
Figure 3splicing of exon 32 is illustrated in the top portion of the figure
Normal
Normal splicing of exon 32 is illustrated in the top portion of the figure. Schematic representation of exon 32 skipping is shown at the lower portion. A 16% acrylamide gel run of the PCR products from cDNA shows the normal splice product of 405 base-pairs and a splice variant band of 310 base-pairs that results in the addition of 8 amino acids followed by a stop
codon. The predicted protein size is 1496 amino acids compared to normal (2261 amino acids). Lane 1 (control), Lane 2
(proband). Note the constitutive splicing in control lane as well as affected. Referent 50 base-pair ladder is shown in lane 3.
Sequence of aberrant splicing shown at bottom of figure.

Other potential constitutive splice sites
investigated
A total of 4 intron/exon junctions that showed low information content were examined for altered splicing events
(Table 1). The intron/exon junction 5/6 revealed normal
splicing. In contrast, the 3 other sites examined demonstrated low levels of aberrant splicing.
Specifically, at the intron 11/exon 12 junction, an aberrant protein product is produced. It consists of correct
splicing through exon 11, followed by exons 12 and 13
that are spliced out of the final product. This results in the
inclusion of 8 novel amino acids after Exon 11 followed
by a stop codon. Secondly, at the intron 28/exon 29 junc-

tion, a splicing defect resulted in the splicing out of exon
29. This product then contains a novel amino acid followed by a stop codon. Finally, at the intron 31/exon 32
junction, in addition to the previously discovered splicing
mutation (exon 32 spliced out), an alternative acceptor
site in IVS31 was identified creating 50 novel amino acids,
followed by a stop codon. All 3 of these splicing defects
were found to occur constitutively at a level less than 1%
of the normal transcript.

Discussion
Following the discovery that mutations in ABCA1 cause
Tangier Disease or familial hypoalphalipoproteinemia
[18-20], more than 90 functional variants [4,8,21] have
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Exon 32 aberrant product B

Exon 31
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Intron 31

Intron 32
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...tcttgtctataaagacccgtatgcttggttttcatgtgatgacagAGAAACAAAA…
Inclusion Intron 31 fragment
Cryptic splice site
Figure
4 transfection PCR products of the minigene construct for IVS31
Top: Post
Top: Post transfection PCR products of the minigene construct for IVS31. Lanes 1 and 2 = IVS31-1g>c (mutant);
Lane 3 = IVS31-1g (wildtype); Lane 4 = untransfected control; Lane 5 = 50 bp ladder. Bottom: Sequence of aberrant product B
containing Exon 31, activation of a cryptic splice site with inclusion of a potion of intron 31 (31 base-pairs), and retention of
Exon 32.
now been reported to cause the low HDL-C phenotype.
The vast majority of these mutations are located in coding
regions, whereas only a few involve intronic areas
[4,8,21,22]. In the present study, alterations in two different intronic regions of ABCA1 were identified resulting in
skipping of exons 7 and 32, the former resulting in
removal of 59 amino acids from the final protein product
and the latter causing a frameshift with a stop codon predicting premature truncation at 1496 AA, compared to the
normal protein, 2261AA.
That the IVS7 mutation did not reveal the level of missplicing expected in the minigene experiment is unclear.
One possibility is the potential influence of non-included
intronic regions. That is, while the IVS7+6t>c mutation is
necessary for mis-splicing to occur, there may be addi-

tional factors required to produce the high levels of missplicing predicted from cDNA analysis. For example, the
size of the intronic regions surrounding the IVS7 mutation may have been excessively large (13 kb) to permit
conditions favoring optimization of the minigene construct. To this end, Ladd and Cooper [23] identified splicing enhancers and suppressors at appreciable distances
from exon/intron junctions. Moreover, Genetta et al [24]
discovered a bipartite intronic splicing enhancer located
2.6 kb downstream from the intron/exon junction
required for exon inclusion. Gatto et al. [25] investigated
intronic regions that control splicing of a fibroblast
growth factor receptor-2 alternative exon and identified a
region located 1 kb downstream from the exon splice site.
This raises the possibility that due to size constraints,
intronic enhancers and/or suppressors may have been
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excluded from our constructs, thereby limiting complete
evaluation of these intronic regions.
Although the majority of human mutations are the result
of missense or nonsense variation in genomic DNA [26],
it has recently been appreciated that aberrant splicing may
also account for a significant proportion of cases [27].
Because mutations are proportional to coding length [28],
large genes such as ABCA1, are more likely to yield splicemediated functional mutations as demonstrated in the
present case. To our knowledge, this represents only the
3rd case of biallelic splicing defects associated with human
pathology. [29,30].
In addition to the mutations reported above, we identified 3 additional defects, all constitutive and at very low
levels (less than 1% compared to the normal transcript).
Two of the newly presented variants result in exon skipping, and the other involves activation of a cyptic splice
site. However, because only trace amounts of these variant
proteins may be produced, it is highly unlikely that they
would bear any physiologic significance. Moreover, the
alternate spliced products occurred with equal frequency
(as determined by densitometry) in all subjects studied,
independent of HDL cholesterol, and therefore unlikely
to be under regulatory control [31,32].
Whereas the identification of two intronic mutations in
ABCA1, located on opposite chromosomes may have predicted the Tangier Disease phenotype, the patient did not
exhibit any of the known clinical features of this disorder
[33]. This may in part reflect the relative inability of the
first splicing defect (IVS7 +6t>c) to completely suppress
some normal protein production as confirmed by densitometry and automated splice site analysis. In the present
case, the haploinsufficiency was the likely result of the
combination of a negative effect of the expressed mutant
isoform resulting from protein termination (splice defect
at exon 31) and post-translational instability as a byproduct of a poorly or non-functioning protein (splice defect
at exon 7) based upon the predicted removal of 59 amino
acids within the extracellular loop. In contrast to affected
family members with premature CHD, the proband is
clinically healthy despite low HDL-C, raising the possibility that in the absence of other CHD risk factors, isolated
low HDL-C may not pose a substantially increased risk of
vascular disease [34].
The ABCA1 splicing mutations observed in the present
case resulted in an approximate 30–50% reduction in
HDL-C with more modest effects on apo AI levels whereas
compound heterozygotes displayed greater reductions in
HDL-C (50–80%) and ApoAI as we previously reported
[22,35].

http://www.biomedcentral.com/1471-2350/10/1

To date, we have identified 15 functional mutations in
ABCA1 (n = 10), LCAT (n = 3) and APOA1 (n = 2) in 20
unrelated probands with very low HDL-C (20 mg/dL or
0.52 mmol/L); three of these mutations are the result of
splicing defects in ABCA1. These data suggest that
although splice mutations in ABCA1 are uncommon, they
are worthy of further consideration, particularly in cases
where promoter and coding regions of candidate genes
fail to identify the genetic basis of very low HDL-C.

Conclusion
We have identified 2 different intronic variants in ABCA1.
This represents the first reported case of distinct splice-site
mutations causing HDL-C deficiency and the third overall
aberrant clinical phenotype occurring as a consequence of
multiple splicing defects.
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